Short Communication - Journal of Pulmonology and Clinical Research (2023) Volume 6, Issue 4

Chronic obstructive pulmonary disease and diffuse parenchymal lung disease are linked to pulmonary hypertension: Emphasis on right ventricular (dys) function

Irene Kneussl ^*

Department of Adult Cardiology, Medical University of Vienna, Vienna, Austria

*Corresponding Author:

Irene Kneussl
> Department of Adult Cardiology
Medical University of Vienna
Vienna, Austria
E-mail: kneussl@ire.ne.at

Received:29-Jun-2023, Manuscript No. AAJPCR-23-106078; Editor assigned:01-July-2023, PreQC No. AAJPCR-23-106078 (PQ); Reviewed:14-July-2023,QC No. AAJPCR-23-106078; Revised:19-July-2023, Manuscript No. AAJPCR-23-105656 (R); Published:26-July-2023, DOI:10.35841/ aajpcr-6.4.157

Citation: Kneussl I. Chronic obstructive pulmonary disease and diffuse parenchymal lung disease are linked to pulmonary hypertension: Emphasis on right ventricular (dys) function. J Pulmonol Clin Res. 2023;6(4):157

Abstract

Introduction

Pulmonary diseases encompass a diverse range of conditions that affect the lungs and respiratory system, posing significant health challenges worldwide. These diseases can be caused by various factors, including infections, inflammation, environmental exposures, genetic predispositions, and lifestyle choices. They can result in impaired lung function, compromised breathing, and reduced quality of life. Pulmonary diseases, such as asthma, Chronic Obstructive Pulmonary Disease (COPD), pneumonia, pulmonary fibrosis, and lung cancer, affect millions of individuals globally and are a leading cause of morbidity and mortality. Understanding the causes, symptoms, diagnosis, and treatment options for pulmonary diseases is vital for healthcare professionals and individuals to effectively manage and mitigate their impact. Moreover, ongoing research and advancements in the field are essential in improving prevention strategies, early detection, and innovative treatments to enhance respiratory health and overall well-being [1].

Chronic Obstructive Pulmonary Disease (COPD) and diffuse parenchymal lung disease (DPLD) are two respiratory conditions that can significantly impact an individual's quality of life and respiratory function. In addition to their distinct characteristics, these diseases have an intriguing association with pulmonary hypertension, a condition characterized by increased blood pressure in the pulmonary arteries. COPD is a chronic inflammatory lung disease primarily caused by long-term exposure to irritants such as tobacco smoke. It encompasses two main conditions: chronic bronchitis, characterized by chronic cough and excessive mucus production, and emphysema, which involves the destruction of lung tissue, leading to impaired airflow. These structural changes in the lungs can contribute to the development of pulmonary hypertension, placing strain on the right side of the heart [2].

On the other hand, DPLD refers to a group of interstitial lung diseases characterized by inflammation and scarring of the lung tissue, leading to reduced lung function and impaired gas exchange. Similar to COPD, DPLD has been associated with the development of pulmonary hypertension, further compromising the function of the right ventricle. The interplay between COPD, DPLD, and pulmonary hypertension underscores the importance of understanding the impact on right ventricular function. The right ventricle is responsible for pumping blood to the lungs for oxygenation, and when faced with increased resistance in the pulmonary arteries, it must work harder to maintain adequate blood flow. Over time, this increased workload can lead to right ventricular dysfunction or failure, exacerbating the overall impact on respiratory function and cardiovascular health [3].

The diagnosis and treatment of CTEPH require a comprehensive and multidisciplinary approach. Accurate diagnosis through a combination of clinical evaluation, imaging techniques, and hemodynamic assessment is essential. Pulmonary endarterectomy remains the gold standard surgical treatment, while riociguat and balloon pulmonary angioplasty offer viable alternatives. Collaborative efforts between healthcare professionals are crucial to optimize patient management and improve long-term outcomes. Further research is necessary to enhance our understanding of CTEPH and explore novel therapeutic approaches to improve patient outcomes [4].

Recognizing the association between these conditions is essential for healthcare professionals in the diagnosis and management of patients. Comprehensive evaluations, including thorough assessments of pulmonary function, imaging studies, and right heart catheterization, may be necessary to fully evaluate the extent of disease involvement and determine appropriate treatment strategies [5].

References

1. Tseng S, Stanziola AA, Sultan S, et al. Pulmonary hypertension related to chronic obstructive pulmonary disease and diffuse parenchymal lung disease: A focus on right ventricular dysfunction. Heart Fail Clin. 2018;14(3):403-116.

Indexed at, Google Scholar,Cross Ref

2. Seeger W, Adir Y, Barbera JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25): 109-16.

Indexed at, Google Scholar, Cross Ref

3. Panagiotou M, Church AC, Johnson MK, et al Pulmonary vascular and cardiac impairment in interstitial lung disease. Eur Respir Rev. 2017;26(143).

Indexed at, Google Scholar, Cross Ref

4. Nathan SD, Hassoun PM.. Pulmonary hypertension due to lung disease and/or hypoxia.. Clin Chest Med. 2013;34(4):695-705.

Indexed at, Google Scholar

5. King CS, Shlobin OA. The trouble with group 3 pulmonary hypertension in interstitial lung disease: Dilemmas in diagnosis and the conundrum of treatment. Chest. 2020;158(4):1651-64.

Indexed at, Google Scholar, Cross Ref